Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID-19.
Where this comes from
- Record sourced from PubMed, PMID 32409436.
- Also identified by DOI 10.3949/ccjm.87a.ccc026.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Analyses of COVID-19 patients with preexisting interstitial lung disease (ILD) or pulmonary sarcoidosis is lacking but registries are ongoing. Treatment of COVID-19 in patients with underlying ILD or sarcoidosis may include hospital admission, possible drug treatment, caution with steroids, and avoidance of mechanical ventilation in acute exacerbation of ILD. Patients with COVID-19 respiratory illness are at risk for developing ILD.